Public Release: 

Coming soon: World's Largest Gastrointestinal Cancer Congress

The 19th ESMO World Congress on Gastrointestinal Cancer takes place in Barcelona, Spain, from 28 June to 1 July 2017

European Society for Medical Oncology

Lugano, Barcelona - June 15, 2017. Around 3,500 oncology professionals and researchers from around the world will learn about the latest advances in the field at the 19th ESMO World Congress on Gastrointestinal Cancer taking place in Barcelona, Spain, from 28 June to 1 July 2017.

The World GI Congress is the premier global event in the field - encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and rare tumours.

Colorectal and stomach cancers are among the most common cancers in the world.1 Many unmet needs exist in certain cancers such as pancreatic, liver and gall bladder cancers, which are among the most common causes of death worldwide.2

There are currently hundreds of ongoing studies in the field of GI malignancies and the ESMO 19th World Congress on Gastrointestinal Cancer will present the latest research with a potential to change outcomes for patients worldwide:

Scientific Programme

Over 425 abstracts were accepted for presentation at the ESMO 19th World Congress on Gastrointestinal Cancer, including research on:

  • Liquid biopsies

  • The role of the microbiome in cancer medicine

  • Immune mechanisms and immune therapy in GI cancer

  • New drugs

  • Molecular markers

Further information on the congress agenda can be found here:

Abstracts presented at World GI Congress will be published on 28 June in a supplement of Annals of Oncology.

Embargo information

Oral and late breaking abstracts selected by the Scientific Committee for presentation at World GI Congress are embargoed until the end of the scientific session during which they are presented. Oral abstracts scheduled for presentation include:

Wednesday, 28 June 2017

  • PEGPH20 Improves PFS in Patients with Metastatic Pancreatic Ductal Adenocarcinoma: A Randomized Phase 2 Study in Combination With nab-Paclitaxel/Gemcitabine +
    Andrew Hendifar, et al., O-003

  • Tumor Hyaluronan May Predict Benefit from PEGPH20 When Added to nab Paclitaxel/Gemcitabine in Patients with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (mPDA)
    Andrew Hendifar, et al., O-028

Thursday, 29 June 2017

  • Nivolumab Monotherapy in Patients with Advanced Gastric of Gastroesophageal Junction (GEJ) Cancer and 2 or More Prior Treatment Regimens: Sub-Analysis of the CheckMate 032 Study
    Patrick Ott, et al., O-007

  • Efficacy and Safety of Nivolumab in Patients with Advanced Hepatocellular Carcinoma Analyzed by Patient Age: A Sub-Analysis of the CheckMate 040 Study
    Ignacio Melero, et al., O-008

  • Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib treatment
    Jordi Bruix, et al., O-009

Friday, 30 June 2017

  • Systematic liquid biopsy identifies novel and heterogeneous mechanisms of acquired resistance in gastrointestinal (GI) cancer patients
    Aparna Parikh, et al., O-001

  • Impact in prognosis of circulating tumor DNA mutant allele fraction (MAF) in RAS mutant metastatic colorectal cancer (mCRC)
    Enrique Sanz-García, et al., O-010

  • RET rearrangements define a new and rare molecular subtype of metastatic colorectal cancer (mCRC)
    Filippo Pietrantonio, et al., O-011

  • Impact of prior bevacizumab treatment of VEGFA and PIGF levels and patient outcomes: A retrospective analysis of baseline plasma samples from the VELOUR trial
    Eric Van Cutsem, et al., O-012

  • The prognostic impact of primary tumor location in patients undergoing resection for colorectal liver metastasis: A propensity score-matched analysis
    Yuichi Goto, et al., O-013

  • Prognostic value of primary tumor location in stage III colon cancer is associated with RAS and BRAF mutational status
    Julien Taieb, et al., O-015

  • Frequency and impact of tumor genotyping in clinical practice of patients with advanced biliary tract cancers (ABTCs)
    Stephanie Reyes, et al., O-021

  • Validation of Nu.Q™ colorectal cancer screening triage test to identify FIT positive individuals at low risk of screen relevant neoplasia
    Mark Eccleston, et al., O-022

  • Mediterranean diet components are negatively associated with advanced colorectal polyps in a population-based case-control study
    Naomi Fliss Isakov, et al., O-023

  • Should a single nucleotide variant in TGFBR1 modify colorectal cancer screening recommendations?
    Garry Mahon, et al., O-024

Saturday, 1 July 2017

  • Central evaluation for surgical treatment options in FIRE-3- updated results and impact on overall survival
    Dominik Modest et al., O-029

  • Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (ML22011)- study
    Dominik Modest, et al., O-026

  • Overall survival analysis of the FOXFIRE, SIRFLOX and FOXFIRE-Global prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer
    Guy van Hazel, et al., O-027 xxx

The World GI Congress will take place in the The International Convention Center of Barcelona (CCIB) and is organized by Imedex.


Notes for Editors


1 International Agency for Research on Cancer (IARC), Globocan 2012.

Stomach and Colorectal Cancers, Estimated Incidence, Mortality and Prevalence Worldwide in 2012:

Colorectal cancer is the third most common cancer in men (746,000 cases, 10.0% of the total) and the second in women (614,000 cases, 9.2% of the total) worldwide. Almost 55% of the cases occur in more developed regions

Almost one million new cases of stomach cancer were estimated to have occurred in 2012 (952,000 cases, 6.8% of the total), making it the fifth most common malignancy in the world, after cancers of the lung, breast, colorectum and prostate.

2 Cancer Research UK

Media Registration

ESMO welcomes media interested in obtaining information and reporting on cancer issues. Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card. Media representatives are required to observe and abide by the ESMO 2017 Media Policy.

Press members may register using this link:

Media registration in advance is strongly recommended.

A Press Working Room will be available to registered journalists:

Meeting venue

The International Convention Center of Barcelona (CCIB)
Rambla de Prim 1-17
08019 Barcelona, Spain

For more information, please contact

ESMO Press Office
Tel: +41 (0)91 973 19 04

About the European Society for Medical Oncology (ESMO)

ESMO is the leading professional organisation for medical oncology. With more than 15,000 members representing oncology professionals from over 130 countries worldwide, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment.

About Imedex

Imedex is the industry leader in developing and delivering independent, accredited healthcare education. The Company's programs specializing in oncology, haematology, and gastroenterology are provided through live events around the world as well as through effective online educational opportunities for on-the-go healthcare providers.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.